Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
UnitedHealth Group Incorporated filed a Form S-3 shelf registration dated March 2, 2026 to register a range of securities, including debt securities, preferred stock, common stock, warrants and guarantees for offerings from time to time after the effective date. The prospectus explains offering mechanics and distribution methods. As context, 907,675,839 shares of common stock were outstanding as of February 20, 2026.
UnitedHealth Group Incorporated has appointed Dennis Stankiewicz, age 48, as Chief Accounting Officer effective March 2, 2026. He will also continue serving as Corporate Controller, a role he has held since April 17, 2023, after joining the company in 2016 as General Auditor.
His compensation includes a $550,000 annual base salary, an initial annual cash bonus target of 85% of base salary, and eligibility for annual and long-term stock-based awards consistent with his seniority. He will receive severance equal to one times base salary if terminated without cause, conditioned on a non-compete during the severance period. The company states he has no related-party transactions requiring disclosure, while current Chief Accounting Officer Tom Roos will become Chief Financial Officer of Optum Insight on March 2, 2026.
UnitedHealth Group is a large, diversified health care and well-being company built around two complementary businesses: Optum and UnitedHealthcare. It is listed on the New York Stock Exchange under the symbol UNH and had 907,675,839 common shares outstanding as of February 20, 2026.
Optum combines Optum Health, Optum Insight and Optum Rx, delivering value-based care, analytics and pharmacy services. In 2025, Optum Rx managed $188 billion in pharmaceutical spending, while Optum Insight reported an aggregate backlog of $31.1 billion, with $18.3 billion expected within 12 months.
UnitedHealthcare provides health benefits to employers, individuals, Medicare and Medicaid beneficiaries, serving tens of millions of people across its Employer & Individual, Medicare & Retirement and Community & State lines. Premium revenues from risk-based products represent nearly 80% of total consolidated revenues, and CMS premium revenues account for 44%. The company employs more than 390,000 people, including nearly 165,000 clinical professionals, and operates under extensive U.S. and international health care, privacy, banking and consumer protection regulations, with detailed risk factors around medical cost trends, technology, cyber security, regulation and competition.
UNITEDHEALTH GROUP INC Chief Accounting Officer Thomas E. Roos reported several equity-related transactions on common stock and options. He was granted 9,768 non-qualified stock options with an exercise right to buy shares, all recorded at a price of
UNITEDHEALTH GROUP INC executive Christopher R. Zaetta, EVP & Chief Legal Officer, reported multiple equity compensation transactions. He received a grant of 28,414 non-qualified stock options, each giving a right to buy UnitedHealth common shares, with the options vesting 25% annually on February 23 from 2027 through 2030.
Zaetta also acquired 7,084 shares of common stock as a grant, described in the footnotes as restricted stock units that vest 25% each year on February 23 from 2027 through 2030. In a related tax-withholding disposition, 129.454 shares of common stock were withheld at $282.34 per share to cover tax obligations, reducing the directly held common stock balance to 9,542.54 shares while increasing total equity awards outstanding.
UNITEDHEALTH GROUP INC executive Timothy John Noel reported new equity awards and a small tax-related share disposition. He received 35,517 non-qualified stock options and 8,855 shares of common stock as grants. The options and the related restricted stock units vest 25% each year on February 23 from 2027 through 2030. To satisfy tax obligations, 123.171 shares of common stock were disposed of at $282.34 per share, leaving him with 17,472.324 common shares directly owned.
UNITEDHEALTH GROUP executive Erin McSweeney reported new equity awards and a related tax share disposition. She was granted 19,535 non-qualified stock options with an exercise right, and 4,871 shares of common stock as a stock award. The filing also shows 130.684 shares of common stock were disposed of at
UNITEDHEALTH GROUP INC executive Patrick Hugh Conway, Chief Executive Officer of Optum, reported equity compensation and a related tax share disposition. He was granted 35,517 non-qualified stock options with an exercise right to buy shares, and 8,855 shares of common stock as a stock award. Both awards vest in four equal installments of 25% on February 23 of each year from 2027 through 2030. To satisfy tax obligations on equity, 178.988 shares of common stock were disposed of at $282.34 per share, leaving him with 18,479.97 common shares held directly after these transactions.
DeVeydt Wayne S reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group’s Chief Financial Officer Wayne S. DeVeydt reported equity awards that increase his direct ownership in the company. He was granted non-qualified stock options for 35,517 shares on
The common stock award and related restricted stock units vest in 25% increments each
UnitedHealth Group updated the terms of a stock option previously granted to Stephen Hemsley. The grant, originally issued on May 14, 2025 with three-year cliff vesting, now carries a two-year share holding requirement after vesting.
Hemsley must hold any net shares obtained from exercising this option until May 14, 2030, reinforcing longer-term alignment with shareholders. The only exceptions are in cases of death or disability, and all other terms of the stock option remain unchanged.